pharma · Glioblastoma · Unresectable or metastatic soft tissue sarcoma
Philogen
Philogen S.p.A.
Philogen S.p.A is a pharma organization headquartered in SIENA, IT. Primary therapeutic focus areas include Glioblastoma, Unresectable or metastatic soft tissue sarcoma, Cutaneous Squamous Cell Carcinoma, locally advance
Company details
- Status
- Public
- HQ
- Loc. Bellaria, 35, Sovicille, SIENA 53018, IT
- Founded
- 1996
- Employees
- 180
- Programs
- 18
- Drugs
- 29
- Patents
- 0
Fibromun, Darleukin
Phase 2 · small molecule · Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)
Fibromun, Darleukin for Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS) is a Phase 2 program (small_molecule) at Philogen S.p.A. with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Philogen S.p.A.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)
- Status
- active
- Trials
- 1